Results 151 to 160 of about 74,767 (306)
PLoS ONEBariatric surgery is another treatment options for patients with obesity, who cannot achieve weight controlled by conservative non-surgical therapy. Although bariatric surgery provides clinical benefits for these patients, it is costly.
Prapaporn Noparatayaporn +6 more
doaj +1 more source
Diabetes, Obesity and Metabolism, EarlyView.ABSTRACT Introduction The risk of delivering a small‐for‐gestational‐age (SGA) neonate is increased after Roux‐en‐Y gastric bypass (RYGB). Because glucose is the foetus's primary energy source and postprandial hypoglycemia is common after RYGB, the Bariatric surgery And consequences for Mother and Baby In pregnancy (BAMBI) study examined associations ...
Louise L. Stentebjerg +6 more
wiley +1 more source
Association Between Glucagon‐Like Peptide‐1 Receptor Agonists and Suicidality: A Systematic Review
Diabetes, Obesity and Metabolism, EarlyView.ABSTRACT Aims We aimed to examine the association between GLP‐1 RA use and suicidal ideation or behaviours through a systematic review of observational studies. Materials and Methods A comprehensive search of MEDLINE, PubMed, EMBASE, CINAHL and PsycINFO was conducted from database inception through December 11, 2025. Observational studies investigating
Timothy H. Chan +5 more
wiley +1 more source
Economic considerations for bariatric surgery and morbid obesity
, 2009 Eldo E Frezza, Mitchell Wacthell1, Bradley Ewing21Center for Metabolic Disease and Texas Tech University, Department of Pathology, 2Rawls Business School, Texas Tech University, Lubbock, TX, USAAbstract: The obesity epidemic is also an economic tragedy ...
Eldo E Frezza +2 more
core
Brain Serotonin Transporter Is Elevated in Obesity: Bayesian and Frequentist Meta‐Analyses
Diabetes, Obesity and Metabolism, EarlyView.ABSTRACT Aims The brain plays a critical role in controlling energy balance. Previous studies have mainly focused on dopaminergic mechanisms, whereas much less attention has been paid to serotonin during the emergence of overweight and obesity. Therefore, this study investigated the association between serotonin transporter (SERT) availability and ...
Kyoungjune Pak
wiley +1 more source
Diabetes, Obesity and Metabolism, EarlyView.ABSTRACT Background In the SELECT trial, semaglutide reduced major adverse cardiovascular outcomes (MACE) in individuals with overweight or obesity and established cardiovascular disease (CVD) but without diabetes. However, real‐world cardiovascular event rates in comparable populations remain uncharacterised.
Viveca Ritsinger +5 more
wiley +1 more source
Diabetes, Obesity and Metabolism, EarlyView.ABSTRACT Aims Access to kidney transplantation (KTx) for people living with obesity and kidney failure is often challenging, especially given the inconsistent availability of publicly funded obesity services across the United Kingdom. This study explored UK kidney healthcare providers' views on weight management support for patients with obesity on ...
Adrian Brown +9 more
wiley +1 more source
Periodontitis and metabolic diseases (diabetes and obesity): Tackling multimorbidity
Periodontology 2000, EarlyView., 2023 Abstract Noncommunicable diseases (NCDs) are multifactorial, long‐term, chronic conditions that represent a burden to health‐care systems worldwide as they can only be controlled rather than cured; hence, they require long‐term care. With the exponential increase in NCDs, the occurrence of individuals presenting with more than one chronic disease is ...
Crystal Marruganti +2 more
wiley +1 more source
Diabetes, Obesity and Metabolism, EarlyView.ABSTRACT Aims Semaglutide, a GLP‐1 receptor agonist, has demonstrated significant weight loss benefits for patients with overweight or obesity in both oral and subcutaneous (s.c.) formulations. Given comparable systemic exposure between formulations, an indirect treatment comparison (ITC) was conducted to confirm comparable efficacy.
Molly Plotkin +6 more
wiley +1 more source